Federal Appeals Court Blocks Mailing of Abortion Pill Mifepristone

A three-judge panel of the 5th U.S. Circuit Court of Appeals unanimously ruled Friday that mifepristone, used in most U.S. abortions, can only be distributed in person at clinics, blocking mail delivery and overruling FDA regulations. The ruling, issued by Republican-appointed judges, represents the biggest shift in abortion policy since the 2022 Supreme Court decision overturning Roe v. Wade and extends nationwide beyond states with abortion bans. Mifepristone, approved in 2000 and used with misoprostol, had its in-person requirements dropped by the FDA during COVID-19 after over 20 years of safety monitoring. About 1 in 4 abortions nationally are prescribed via telehealth, with more women in ban states obtaining abortions this way than by traveling. Manufacturer Danco Laboratories is seeking emergency Supreme Court relief, while the ruling takes immediate effect as appeals proceed.

Federal Appeals Court Ruling Restricting Mifepristone Distribution

• ▪The 5th U.S. Circuit Court of Appeals ruling is in effect as the case works its way through the courts
• ▪All three judges on the 5th U.S. Circuit Court of Appeals panel were nominated by Republican presidents
• ▪The 5th U.S. Circuit Court of Appeals ruling overruled regulations set by the federal Food and Drug Administration regarding mifepristone distribution
• ▪The 5th U.S. Circuit Court of Appeals ruling extends beyond Louisiana and states with abortion bans
• ▪The 5th U.S. Circuit Court of Appeals ruling requires that mifepristone be distributed only in person and at clinics
• ▪The 5th U.S. Circuit Court of Appeals mifepristone ruling is the biggest jolt to abortion policy in the U.S. since the 2022 Supreme Court ruling that overturned Roe v. Wade
• ▪A three-judge panel of the New Orleans-based 5th U.S. Circuit Court of Appeals issued a unanimous ruling blocking the mailing of mifepristone prescriptions on Friday

Mifepristone's Role in U.S. Abortion Access and Telehealth

• ▪Mifepristone was approved in 2000 as a safe and effective way to end early pregnancies
• ▪FDA officials under President Joe Biden said that after more than 20 years of monitoring mifepristone use and reviewing dozens of studies involving thousands of women, it was clear that women could safely use the pill without direct supervision

Legal Precedent and FDA Authority Over Drug Regulation

• ▪The 5th U.S. Circuit Court of Appeals judges noted in their ruling that the FDA could not say when the mifepristone safety review might be complete and admitted the FDA was still collecting data

Potential Supreme Court Appeal and Political Reactions

• ▪Danco Laboratories said it will file an emergency appeal with the Supreme Court if the 5th U.S. Circuit Court of Appeals does not grant its request for a one-week hold
• ▪The 5th U.S. Circuit Court of Appeals mifepristone ruling is likely to be appealed to the U.S. Supreme Court
• ▪The Supreme Court's 2024 mifepristone decision sidestepped the core issues by ruling that the anti-abortion doctors behind the case didn't have legal standing to sue
• ▪Danco Laboratories asked the 5th U.S. Circuit Court of Appeals on Friday after the ruling to put its order on hold for one week to give the company time to seek relief from the Supreme Court
• ▪The conservative-majority Supreme Court overturned abortion as a nationwide right in 2022
• ▪The Supreme Court unanimously preserved access to mifepristone in 2024

Perspective of Abortion rights advocates and ACLU

• ▪Julia Kaye of the ACLU views the 5th U.S. Circuit Court of Appeals mifepristone ruling as an unprecedented judicial interference with FDA scientific authority

Perspective of Anti-abortion organizations

• ▪Marjorie Dannenfelser of Susan B. Anthony Pro-Life America characterized the 5th U.S. Circuit Court of Appeals mifepristone ruling as a victory for women's safety
• ▪Carol Tobias of the National Right to Life Committee praised the 5th U.S. Circuit Court of Appeals mifepristone ruling as protecting unborn children

Perspective of Mifepristone manufacturers Danco Laboratories and GenBioPro

• ▪Danco Laboratories argues that the 5th U.S. Circuit Court of Appeals mifepristone ruling ignores decades of safety data and FDA expertise